Difference between revisions of "Resource:E273cee3-0907-4841-9126-9cee08518338"

From The Embassy of Good Science
(Created page with "{{Resource |Resource Type=Cases |Title=Up, Up, and Away: Clinical Trials Go International |Is About=. |Important Because=. |Important For=Researchers }} {{Link |Has Link=https...")
 
 
(4 intermediate revisions by 2 users not shown)
Line 2: Line 2:
 
|Resource Type=Cases
 
|Resource Type=Cases
 
|Title=Up, Up, and Away: Clinical Trials Go International
 
|Title=Up, Up, and Away: Clinical Trials Go International
|Is About=.
+
|Is About=This is a short interview with a research who describes some of the ethical issues that arise from running international clinical trials. The researcher gives the example of the fictional US based company Rx who wants to run a trial in Russia for a certain medication. One reason for such a company to 'outsource' a clinical trial is lower costs in other countries. Questions asked in the case include 'what is the quality of the informed consent?' and 'can you promise participants to receive a certain drug for the study period, but not afterwards?'
|Important Because=.
+
|Important Because=As described in the case:  "Clinical trials are one of the most expensive steps in pharmaceutical and device development for biomedical companies. Each phase of the trial can cost up to twenty million dollars to run."<ref>https://www.scu.edu/ethics/focus-areas/bioethics/resources/up-up-and-away-clinical-trials-go-international/</ref>  However, clinical trials are an important step to ensure the efficiency, safety and dosage of a drug.
|Important For=Researchers
+
<references />
 +
|Important For=Researchers; PhD students; Research integrity trainers
 
}}
 
}}
 
{{Link
 
{{Link
 
|Has Link=https://www.scu.edu/ethics/focus-areas/bioethics/resources/up-up-and-away-clinical-trials-go-international/
 
|Has Link=https://www.scu.edu/ethics/focus-areas/bioethics/resources/up-up-and-away-clinical-trials-go-international/
 
}}
 
}}
{{Related To}}
+
{{Related To
 +
|Related To Resource=Resource:08657792-f22e-486e-a034-c78fb9a2f39f;Resource:4c1137a3-8b5e-411e-bc98-18ae6818d7b8
 +
|Related To Theme=Theme:9ac8c1db-f98b-41ee-858d-a8c93a647108
 +
}}
 
{{Tags
 
{{Tags
 
|Has Virtue And Value=Accountability
 
|Has Virtue And Value=Accountability
|Has Good Practice And Misconduct=Informed consent; Volantary participation
+
|Has Good Practice And Misconduct=Informed consent; Volantary participation; International research; Clinical trials
 
|Related To Research Area=Clinical medicine
 
|Related To Research Area=Clinical medicine
 
}}
 
}}

Latest revision as of 14:03, 14 October 2020

Cases

Up, Up, and Away: Clinical Trials Go International

What is this about?

This is a short interview with a research who describes some of the ethical issues that arise from running international clinical trials. The researcher gives the example of the fictional US based company Rx who wants to run a trial in Russia for a certain medication. One reason for such a company to 'outsource' a clinical trial is lower costs in other countries. Questions asked in the case include 'what is the quality of the informed consent?' and 'can you promise participants to receive a certain drug for the study period, but not afterwards?'

Why is this important?

As described in the case: "Clinical trials are one of the most expensive steps in pharmaceutical and device development for biomedical companies. Each phase of the trial can cost up to twenty million dollars to run."[1] However, clinical trials are an important step to ensure the efficiency, safety and dosage of a drug.

For whom is this important?

Other information

Cookies help us deliver our services. By using our services, you agree to our use of cookies.
5.1.6